drugset
drugset / Trial / NCT06525246

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

NCT06525246 ↗

Phase 1 Completed 78 enrolled Ono Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the tolerability and safety of ONO-7475 in combination with osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV or recurrent non-small cell lung cancer (NSCLC), which is unsuitable for radical irradiation.

Timeline

Start
2021-08-06
Primary completion
2025-06-23
Completion
2025-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamnorzatinib Small molecule — —
Background Osimertinib Small molecule — —

Indications

non-small cell lung carcinoma